Alumis Inc.
ALMS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$6.78
KIRA · Stoqly’s AI analyst, in plain words
- Alumis Inc. had $24.1M of revenue in fiscal 2025.
- Its operating margin was −1,886.9%: of every 100 in sales, about −1,887 is left after running the business.
- Alumis Inc. lost $243M in fiscal 2025.
- Free cash flow was −$370M in fiscal 2025, −1,539.2% of revenue.
- Alumis Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 200.0%.
Market cap
$866M
P/E
—
Revenue
$24.1M
Net income
−$243M
Free cash flow
−$370M
Operating margin
−1,886.9%
Alumis Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−1,011.7%
No. It lost money last year.
Does profit turn into cash?
−1,539.2%
No. It spent more cash than it brought in.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Alumis Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- ALUMIS INC.
- CIK
- 0001847367
Alumis Inc. · ALMS
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | — | — | $24.1M |
| Operating margin | — | — | −1,886.9% |
| Net income | −$155M | −$294M | −$243M |
| Net margin | — | — | −1,011.7% |
| Diluted EPS | −$72.08 | −$10.38 | −$2.86 |
| Cash | |||
| Cash from operations | −$130M | −$255M | −$370M |
| Capital expenditure | $4.5M | $1.7M | $0.7M |
| Free cash flow | −$134M | −$257M | −$370M |
| FCF margin | — | — | −1,539.2% |
| Share buybacks | $0.1M | $0.0M | $0.0M |
| Share count change | — | 1,218.1% | 200.0% |
| Debt and strength | |||
| Cash and short-term investments | $49.0M | $288M | $309M |
| Shareholders' equity | −$339M | $260M | $301M |
| Current ratio | 2.6x | 6.0x | 4.3x |
| Returns and quality | |||
| Return on equity | — | — | −86.7% |
| Return on tangible equity | — | −113.1% | −80.8% |
| Altman Z'' | −29.4 | −3.9 | −7.8 |
Insiders bought, 12 months
$45.0M
4 insiders
Insiders sold, 12 months
$1.5M
7 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alumis Inc. · ALMS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.78 a share, the company is worth $866M.
Source: SEC EDGAR XBRL filings (CIK 0001847367). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.